Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.41B |
| 2 |
ExxonMobil
XOM
|
+$937M |
| 3 |
Eli Lilly
LLY
|
+$875M |
| 4 |
Tesla
TSLA
|
+$749M |
| 5 |
GE Aerospace
GE
|
+$740M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$1.99B |
| 2 |
Deutsche Bank
DB
|
+$1.49B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1.12B |
| 4 |
Broadcom
AVGO
|
+$1.12B |
| 5 |
Amgen
AMGN
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.51% |
| 2 | Healthcare | 16.3% |
| 3 | Consumer Discretionary | 11.31% |
| 4 | Industrials | 10.9% |
| 5 | Financials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Nike
NKE
$60.1B
| $290M | 0.09% |
2,841,613
-882,884
| -24% | -$104M |
|
177
Chubb
CB
$132B
| $280M | 0.09% |
1,426,514
+869,400
| +156% | +$179M |
|
178
Kimco Realty
KIM
$16.2B
| $279M | 0.09% |
14,105,157
+1,020,376
| +8% | +$23.4M |
|
179
Penumbra
PEN
$12.9B
| $276M | 0.09% |
2,212,361
-285,257
| -11% | -$45.3M |
|
180
Stanley Black & Decker
SWK
$15.5B
| $275M | 0.09% |
2,626,589
-429,093
| -14% | -$52.8M |
|
181
CubeSmart
CUBE
$9.28B
| $274M | 0.09% |
6,411,021
+3,777,484
| +143% | +$174M |
|
|
TIXT
182
DELISTED
TELUS International
TIXT
| $270M | 0.08% |
10,754,539
+2,432,594
| +29% | +$57.5M |
|
183
Paycom
PAYC
$9.52B
| $269M | 0.08% |
961,285
-23,853
| -2% | -$7.04M |
|
184
Zimmer Biomet
ZBH
$18.7B
| $266M | 0.08% |
2,531,394
-809,014
| -24% | -$96M |
|
185
Sea Limited
SE
$78.5B
| $263M | 0.08% |
3,936,098
+14,040
| +0.4% | +$1.2M |
|
|
PXD
186
DELISTED
Pioneer Natural Resource Co.
PXD
| $260M | 0.08% |
1,166,855
-112,676
| -9% | -$28.6M |
|
187
American Electric Power
AEP
$67.9B
| $258M | 0.08% |
2,685,368
-3,433,785
| -56% | -$340M |
|
188
Monster Beverage
MNST
$90.1B
| $250M | 0.08% |
10,789,568
+4,520
| +0% | +$98.3K |
|
189
Nutrien
NTR
$32.1B
| $250M | 0.08% |
3,131,298
-964
| -0% | -$93.6K |
|
190
Nu Holdings
NU
$65.5B
| $246M | 0.08% |
65,857,366
+16,605,125
| +34% | +$84.2M |
|
191
SouthState Bank Corp
SSB
$10.7B
| $244M | 0.08% |
3,164,079
-887,207
| -22% | -$69.1M |
|
|
APTV.PRA
192
DELISTED
Aptiv PLC 5.50% Series A Mandatory Convertible Preferred Shares
APTV.PRA
| $242M | 0.08% |
2,299,808
+12
| +0% | +$1.42K |
|
193
GSK
GSK
$101B
| $242M | 0.08% |
4,454,158
-1,013
| -0% | -$55.9K |
|
194
Helen of Troy
HELE
$696M
| $242M | 0.08% |
1,491,137
+472
| +0% | +$89K |
|
195
CVS Health
CVS
$121B
| $240M | 0.07% |
2,595,246
+4,921
| +0.2% | +$480K |
|
196
Lam Research
LRCX
$408B
| $239M | 0.07% |
5,616,630
+2,318,680
| +70% | +$110M |
|
197
Air Products & Chemicals
APD
$67.7B
| $239M | 0.07% |
995,128
+226,154
| +29% | +$55M |
|
198
Xcel Energy
XEL
$49.1B
| $239M | 0.07% |
3,375,165
-893
| -0% | -$65K |
|
199
Sherwin-Williams
SHW
$87.4B
| $237M | 0.07% |
1,059,233
| – | – |
|
200
ZTO Express
ZTO
$17.6B
| $237M | 0.07% |
8,640,092
+3,223
| +0% | +$82.6K |
|
Similar funds
Capital Research Global Investors's Q2 2022 Portfolio in Review
As of Q2 2022, Capital Research Global Investors held 461 positions worth $321B, down 21% from $405B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Capital Research Global Investors withdrew a net $12.2B in Q2 2022, closing 38 positions and reducing 158 holdings. Its most notable exit was Deutsche Bank, an estimated $1.49B position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Capital Research Global Investors opened a new position in Eli Lilly worth $945M.
- Capital Research Global Investors's largest Q2 2022 buy was Eli Lilly: 2,914,107 shares worth $945M.
- Capital Research Global Investors added most to AbbVie in Q2 2022, an estimated $1.41B increase.
- Capital Research Global Investors's biggest Q2 2022 reduction was JPMorgan Chase, cutting an estimated $1.99B.
- Capital Research Global Investors fully exited Deutsche Bank in Q2 2022, selling an estimated $1.49B.
- Capital Research Global Investors's ten largest holdings make up 29% of its $321B portfolio in Q2 2022.
- Capital Research Global Investors opened 21 new positions and closed 38 in Q2 2022.
- Capital Research Global Investors's portfolio value fell 21% quarter-over-quarter to $321B.
Based on Capital Research Global Investors's 13F filing for Q2 2022, filed 15 Aug 2022.